Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
nandrolone decanoate androgen receptor small molecule NA drugbank , DGIDB Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
0.22 approved,illicit agonist
nandrolone decanoate dopamine receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit modulator
nandrolone decanoate dopamine receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit modulator
nandrolone decanoate dopamine receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit modulator
nandrolone decanoate dopamine receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit modulator
nandrolone decanoate dopamine receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit modulator
nandrolone decanoate proto-oncogene c-fos small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit inducer
nandrolone decanoate 5-hydroxytryptamine receptor 1b small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit modulator
nandrolone decanoate 5-hydroxytryptamine 2 receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit modulator
nandrolone decanoate 5-hydroxytryptamine 2 receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit modulator
nandrolone decanoate 5-hydroxytryptamine 2 receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit modulator
nandrolone decanoate insulin-like growth factor 1 receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Kidney Failure[MeSHID:D051437]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Senility[MeSHID:D000375]
Anemia[MeSHID:D000740]
NA approved,illicit inducer
click here to return to the previous page